Stanford Gets Grant for Lymphoma Vaccine Research

Stanford University researchers won a $6.25 million grant from the Leukemia & Lymphoma Society today.

The money will be spent to create a special research center for interdisciplinary work on a possible lymphoma vaccine. Researchers on the project come from the university's departments of medicine, oncology, molecular pharmacology, health research and policy, chemical engineering and from the Stanford Genome Center. Ronald Levy, M.D. (right), a Stanford medical professor and chief of the university's oncology division, will oversee the program. He developed the lymphoma drug Rituxan for Genentech Inc.

Researchers in the program will try to create a vaccine that is tailored to each patient's specific lymphoma. Such a vaccine would attack a patient's cancer cells without hurting the immune system the way traditional chemotherapy does.

LymphomaInfo Social